Literature DB >> 19550437

CRTAP mutations in lethal and severe osteogenesis imperfecta: the importance of combining biochemical and molecular genetic analysis.

Fleur S Van Dijk1, Isabel M Nesbitt, Peter G J Nikkels, Ann Dalton, Ernie M H F Bongers, Jiddeke M van de Kamp, Yvonne Hilhorst-Hofstee, Nicolette S Den Hollander, Augusta M A Lachmeijer, Carlo L Marcelis, Gita M B Tan-Sindhunata, Rick R van Rijn, Hanne Meijers-Heijboer, Jan M Cobben, Gerard Pals.   

Abstract

Autosomal recessive lethal and severe osteogenesis imperfecta (OI) is caused by the deficiency of cartilage-associated protein (CRTAP) and prolyl-3-hydroxylase 1 (P3H1) because of CRTAP and LEPRE1 mutations. We analyzed five families in which 10 individuals had a clinical diagnosis of lethal and severe OI with an overmodification of collagen type I on biochemical testing and without a mutation in the collagen type I genes. CRTAP mutations not described earlier were identified in the affected individuals. Although it seems that one important feature of autosomal recessive OI due to CRTAP mutations is the higher consistency of radiological features with OI type II-B/III, differentiation between autosomal dominant and autosomal recessive OI on the basis of clinical, radiological and biochemical investigations proves difficult in the affected individuals reported here. These observations confirm that once a clinical diagnosis of OI has been made in an affected individual, biochemical testing for overmodification of collagen type I should always be combined with molecular genetic analysis of the collagen type I genes. If no mutations in the collagen type I genes are found, additional molecular genetic analysis of the CRTAP and LEPRE1 genes should follow. This approach will allow proper identification of the genetic cause of lethal or severe OI, which is important in providing prenatal diagnosis, preimplantation genetic diagnosis and estimating recurrence risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19550437      PMCID: PMC2987020          DOI: 10.1038/ejhg.2009.75

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  25 in total

Review 1.  Procollagen trafficking, processing and fibrillogenesis.

Authors:  Elizabeth G Canty; Karl E Kadler
Journal:  J Cell Sci       Date:  2005-04-01       Impact factor: 5.285

Review 2.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

3.  Disrupted growth plates and progressive deformities in osteogenesis imperfecta as a result of the substitution of glycine 585 by valine in the alpha 2 (I) chain of type I collagen.

Authors:  W G Cole; D Chan; C W Chow; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1996-11       Impact factor: 6.318

4.  Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen.

Authors:  P H Byers; P Tsipouras; J F Bonadio; B J Starman; R C Schwartz
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

5.  Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations.

Authors:  J Körkkö; L Ala-Kokko; A De Paepe; L Nuytinck; J Earley; D J Prockop
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

6.  Recurrence risks and prognosis in severe sporadic osteogenesis imperfecta.

Authors:  E M Thompson; I D Young; C M Hall; M E Pembrey
Journal:  J Med Genet       Date:  1987-07       Impact factor: 6.318

7.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Authors:  G A Wallis; B Sykes; P H Byers; C G Mathew; D Viljoen; P Beighton
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

8.  Dominant mutations in familial lethal and severe osteogenesis imperfecta.

Authors:  L Cohen-Solal; J Bonaventure; P Maroteaux
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

9.  Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a dominant mutation in a human type I collagen gene (COL1A1).

Authors:  D H Cohn; B J Starman; B Blumberg; P H Byers
Journal:  Am J Hum Genet       Date:  1990-03       Impact factor: 11.025

10.  Mutation analysis of coding sequences for type I procollagen in individuals with low bone density.

Authors:  L D Spotila; A Colige; L Sereda; C D Constantinou-Deltas; M P Whyte; B L Riggs; J L Shaker; T D Spector; E Hume; N Olsen
Journal:  J Bone Miner Res       Date:  1994-06       Impact factor: 6.741

View more
  15 in total

1.  Deficiency of CRTAP in non-lethal recessive osteogenesis imperfecta reduces collagen deposition into matrix.

Authors:  M Valli; A M Barnes; A Gallanti; W A Cabral; S Viglio; M A Weis; E Makareeva; D Eyre; S Leikin; F Antoniazzi; J C Marini; M Mottes
Journal:  Clin Genet       Date:  2011-10-19       Impact factor: 4.438

2.  Comparative X-ray morphometry of prenatal osteogenesis imperfecta type 2 and thanatophoric dysplasia: a contribution to prenatal differential diagnosis.

Authors:  Maria Pia Bondioni; Ugo Ernesto Pazzaglia; Claudia Izzi; Giuseppe Di Gaetano; Francesco Laffranchi; Maurizia Baldi; Federico Prefumo
Journal:  Radiol Med       Date:  2017-07-03       Impact factor: 3.469

Review 3.  Role of cartilage-associated protein in skeletal development.

Authors:  Roy Morello; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2010-06       Impact factor: 5.096

4.  Severe osteogenesis imperfecta caused by a small in-frame deletion in CRTAP.

Authors:  I M Ben Amor; F Rauch; K Gruenwald; M Weis; D R Eyre; P Roughley; F H Glorieux; R Morello
Journal:  Am J Med Genet A       Date:  2011-09-30       Impact factor: 2.802

5.  Evidence for a de novo, dominant germ-line mutation causative of osteogenesis imperfecta in two Red Angus calves.

Authors:  Jessica L Petersen; Shauna M Tietze; Rachel M Burrack; David J Steffen
Journal:  Mamm Genome       Date:  2019-02-20       Impact factor: 2.957

6.  An additional function of the rough endoplasmic reticulum protein complex prolyl 3-hydroxylase 1·cartilage-associated protein·cyclophilin B: the CXXXC motif reveals disulfide isomerase activity in vitro.

Authors:  Yoshihiro Ishikawa; Hans Peter Bächinger
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

7.  Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding.

Authors:  Aileen M Barnes; Erin M Carter; Wayne A Cabral; MaryAnn Weis; Weizhong Chang; Elena Makareeva; Sergey Leikin; Charles N Rotimi; David R Eyre; Cathleen L Raggio; Joan C Marini
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Generalized connective tissue disease in Crtap-/- mouse.

Authors:  Dustin Baldridge; Jennifer Lennington; MaryAnn Weis; Erica P Homan; Ming-Ming Jiang; Elda Munivez; Douglas R Keene; William R Hogue; Shawna Pyott; Peter H Byers; Deborah Krakow; Daniel H Cohn; David R Eyre; Brendan Lee; Roy Morello
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

Review 9.  Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta.

Authors:  Joan C Marini; Wayne A Cabral; Aileen M Barnes
Journal:  Cell Tissue Res       Date:  2009-10-28       Impact factor: 5.249

10.  Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen.

Authors:  Ulrike Schwarze; Tim Cundy; Shawna M Pyott; Helena E Christiansen; Madhuri R Hegde; Ruud A Bank; Gerard Pals; Arunkanth Ankala; Karen Conneely; Laurie Seaver; Suzanne M Yandow; Ellen Raney; Dusica Babovic-Vuksanovic; Joan Stoler; Ziva Ben-Neriah; Reeval Segel; Sari Lieberman; Liesbeth Siderius; Aida Al-Aqeel; Mark Hannibal; Louanne Hudgins; Elizabeth McPherson; Michele Clemens; Michael D Sussman; Robert D Steiner; John Mahan; Rosemarie Smith; Kwame Anyane-Yeboa; Julia Wynn; Karen Chong; Tami Uster; Salim Aftimos; V Reid Sutton; Elaine C Davis; Lammy S Kim; Mary Ann Weis; David Eyre; Peter H Byers
Journal:  Hum Mol Genet       Date:  2012-09-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.